Terms: = Endocrine gland cancer AND TET1, KIAA1676, 80312, ENSG00000138336, CXXC6, bA119F7_1, Q8NFU7, LCX AND Treatment
31484 results:
1. Overweight as a biomarker for concomitant thyroid cancer in patients with Graves' disease.
Park J; An S; Bae JS; Kim JS; Kim K
Front Endocrinol (Lausanne); 2024; 15():1382124. PubMed ID: 38711981
[TBL] [Abstract] [Full Text] [Related]
2. treatment strategies for borderline resectable pancreatic neuroendocrine tumors: a narrative review.
Chang JY; Ruff SM; Cloyd JM
Chin Clin Oncol; 2024 Apr; 13(2):25. PubMed ID: 38711178
[TBL] [Abstract] [Full Text] [Related]
3. Active surveillance is a feasible and safe strategy in selected patients with papillary thyroid cancer and suspicious cervical lymph nodes detected after thyroidectomy.
Solórzano M; Lustig N; Mosso L; Espinoza M; Santana R; Gonzalez H; Montero PH; Cruz F; Solar A; Domínguez JM
Arch Endocrinol Metab; 2024 May; 68():e230146. PubMed ID: 38709151
[TBL] [Abstract] [Full Text] [Related]
4. The prophylactic antiemetic therapies in management of differentiated thyroid cancer patients with radioactive iodine therapy: a single-center, non-randomized clinical trial.
Li X; Cao J; Wang W; Zhu X; Sun Y; Song L; Zhang W; Han Y
Front Endocrinol (Lausanne); 2024; 15():1310223. PubMed ID: 38706697
[TBL] [Abstract] [Full Text] [Related]
5. Perioperative management of a patient with unexpectedly detected early-stage ovarian mucinous carcinoma combined with progressive bulbar paralysis: a case report and literature review.
Zhang D; Xu R; Huo T; Liu Y; Hao Z; Sun Y; Xi X; Du X; Wang L; Du J
BMC Womens Health; 2024 May; 24(1):274. PubMed ID: 38704534
[TBL] [Abstract] [Full Text] [Related]
6. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination-deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial.
Belotte J; Felicetti B; Baines AJ; YoussefAgha A; Rojas-Espaillat L; Ortiz AG; Provencher D; Vázquez RM; Cortijo LG; Zeng X
Trials; 2024 May; 25(1):301. PubMed ID: 38702828
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis.
Chen Y; Liu X; Hu Y; Xia L
Medicine (Baltimore); 2024 May; 103(18):e38019. PubMed ID: 38701316
[TBL] [Abstract] [Full Text] [Related]
8. Incidentally detected follicular thyroid carcinoma mimicking parathyroid adenoma on Tc-99m MIBI scan: A case report.
Han YH; Jeong HJ; Lee SY; Lim ST
Medicine (Baltimore); 2024 May; 103(18):e38107. PubMed ID: 38701245
[TBL] [Abstract] [Full Text] [Related]
9. OTUB2 silencing promotes ovarian cancer via mitochondrial metabolic reprogramming and can be synthetically targeted by CA9 inhibition.
Nan Y; Wu X; Luo Q; Chang W; Zhao P; Zhang L; Liu Z
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2315348121. PubMed ID: 38701117
[TBL] [Abstract] [Full Text] [Related]
10. Score based on contrast-enhanced ultrasound predict central lymph node metastasis in papillary thyroid cancer.
He L; Chen X; Hu J; Meng Y; Zhang Y; Chen W; Fan Y; Li T; Fang J
Front Endocrinol (Lausanne); 2024; 15():1336787. PubMed ID: 38699389
[TBL] [Abstract] [Full Text] [Related]
11. Antitumor activity of extracellular signal-regulated kinases 1/2 inhibitor BVD-523 (ulixertinib) on thyroid cancer cells.
Chen Y; Xiao X; Hu G; Liu R; Xue J
J Cancer Res Ther; 2024 Apr; 20(2):570-577. PubMed ID: 38687926
[TBL] [Abstract] [Full Text] [Related]
12. pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.
Dutta D; Ray P; De A; Ghosh A; Hazra RS; Ghosh P; Banerjee S; Diaz FJ; Upadhyay SP; Quadir M; Banerjee SK
PLoS One; 2024; 19(4):e0297749. PubMed ID: 38687749
[TBL] [Abstract] [Full Text] [Related]
13. E2F transcription factors promote tumorigenicity in pancreatic ductal adenocarcinoma.
Bertonnier-Brouty L; Andersson J; Kaprio T; Hagström J; Bsharat S; Asplund O; Hatem G; Haglund C; Seppänen H; Prasad RB; Artner I
Cancer Med; 2024 May; 13(9):e7187. PubMed ID: 38686617
[TBL] [Abstract] [Full Text] [Related]
14. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract] [Full Text] [Related]
15. [Computer-aided prediction and molecular mechanism investigation of active components in compound Kushen injection inhibiting p21-activated kinase 1].
Lin L; Chang J; Tian Y; Chen J
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2024 Apr; 41(2):313-320. PubMed ID: 38686412
[TBL] [Abstract] [Full Text] [Related]
16. Oral Delivery of Photopolymerizable Nanogels Loaded with Gemcitabine for Pancreatic cancer Therapy: Formulation Design, and in vitro and in vivo Evaluations.
Yugatama A; Huang YL; Hsu MJ; Lin JP; Chao FC; Lam JKW; Hsieh CM
Int J Nanomedicine; 2024; 19():3753-3772. PubMed ID: 38686338
[TBL] [Abstract] [Full Text] [Related]
17. The clinical value of iodine-125 seed implantation in the treatment of iodine-refractory differentiated thyroid carcinoma.
Wan Q; Tan L; Tang X; Wang W; Su Y; Wu Z; Ke M; Chen Z
Front Endocrinol (Lausanne); 2024; 15():1327766. PubMed ID: 38686207
[TBL] [Abstract] [Full Text] [Related]
18. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract] [Full Text] [Related]
19. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study.
Pasternak B; Wintzell V; Hviid A; Eliasson B; Gudbjörnsdottir S; Jonasson C; Hveem K; Svanström H; Melbye M; Ueda P
BMJ; 2024 Apr; 385():e078225. PubMed ID: 38683947
[TBL] [Abstract] [Full Text] [Related]
20. Understanding autoimmune pancreatitis: Clinical features, management challenges, and association with malignancies.
Christodoulidis G; Kouliou MN; Koumarelas KE
World J Gastroenterol; 2024 Apr; 30(15):2091-2095. PubMed ID: 38681985
[TBL] [Abstract] [Full Text] [Related]
[Next]
